Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: Rucaparib in Urothelial Carcinoma
NCT03397394Phase 2Terminated
- Sponsor
- pharma&
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of rucaparib in urothelial carcinoma (UC), sponsored by pharma&. Started Jun 2018; status: terminated.
02
Drugs
rucaparib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03397394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397394.